Medicine :治疗症状性烟雾病,手术优于保守治疗!

2016-01-21 phylis 译 MedSci原创

治疗烟雾病(MMD)是有争议的,往往取决于医生的经验。此外,治疗烟雾病手术方式很多。在这项研究中,研究进行了一项荟萃分析确定是否手术治疗优于保守治疗,并提供一个适当的外科治疗方式。通过在线数据库系统(PubMed、Web of Science、Elsevier Science Direct、和Springer Link)识别与MDD相关的人类病例对照研究。当存在一致性时,应用固定效应模型。否则,则

烟雾病(MMD)的治疗是往往取决于医生的经验的,是存在争议的。此外,治疗烟雾病手术方式也有很多。

在这项研究中,研究人员进行了一项荟萃分析拟确定手术治疗是否优于保守治疗,并提供一个适当的外科治疗方式。通过在线数据库系统(PubMed、Web of Science、Elsevier Science Direct、和Springer Link)识别与MMD相关的人类病例,进行对照研究。当存在一致性时,应用固定效应模型。否则,则利用随机效应模型。

这项荟萃分析包括16项研究。手术治疗能显著降低卒中风险(OR:0.17,95% CI:0.12-0.26)。亚组分析显示,手术治疗更有利于出血性的MMD(OR 0.23,95% CI: 0.15-0.38)的治疗,手术治疗与保守治疗对缺血性烟雾病治疗无显著性差异(OR: 0.45,95% CI,0.15-1.29)。

进一步的分析表明,与直接搭桥手术相比,间接搭桥手术对继发中风风险降低效力较低(OR: 1.79,95% CI,1.14-2.82),而围手术期并发症无显著性差异。

手术是症状性烟雾病患者有效的治疗方法,直接搭桥手术对这些患者更有利。

原文出处:

Qian C, Yu X, et al. The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis. Medicine (Baltimore). 2015 Dec.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-06-28 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-09-04 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-27 李继凯

    文章很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773527, encodeId=6c8b1e735271d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 28 21:44:00 CST 2016, time=2016-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858655, encodeId=eb681858655d5, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Sep 04 10:44:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61083, encodeId=713d610833c, content=文章很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:33:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508902, encodeId=f4761508902f9, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577457, encodeId=3fac15e745730, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606830, encodeId=9673160683092, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 23 13:44:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]

相关资讯

Nature:白内障治疗或告别手术时代,用眼药水即可

白内障作为一种常见的眼科疾病,模糊了世界各地数百万计患者的双眼。在美国,40岁以上的人中几乎超过17.2%患有白内障。目前,治疗白内障唯一的方法是手术,有时需要更换晶状体。然而,7月22日发表在《自然》杂志上的一项研究中,一个科学家团队和眼科医生们通过在狗中检测一种新的治疗方案发现,含有类固醇的滴眼液能够提高患有白内障狗的晶状体透明度。尽管科学家们还不能完全解释白内障是如何形成的,但是他们知道患者

JACC:类癌性心脏病(CaHD)手术治疗早期和晚期预后(27年结果)

类癌综合征患者的症状和生存率都有所改善,但发展为类癌性心脏病(CaHD)还会继续降低生存率。本研究旨在分析瓣膜手术治疗CaHD后患者在27年的时间中的治疗效果,确定早期和晚期的结果,以提高病人护理。研究人员回顾性研究了在1985年至2012年间在本机构所有连续的CAHD患者接受瓣膜置换的短期和长期结果。研究人员对195例CaHD患者的记录进行了分析。在178例患者中的125例(70%)术前纽约心脏

Circulation:B型主动脉夹层治疗:如何选择?

休斯敦德克萨斯大学医学院Afifi RO等人研究了B型主动脉夹层患者的远期结局,成果发表在8月份Circulation期刊上。背景:主动脉夹层(Aortic Dissection,AD)是最主要的主动脉上的灾难性疾病。在血管腔内时代,急性B型主动脉夹层(acute type B aortic dissection, ATBAD)的治疗最引入注目。本项研究旨在评估我们中心治疗时间已经超过13年ATB

阑尾炎手术治疗被颠覆了吗?

如果你得了急性阑尾炎,是选择手术切除还是使用抗生素保守治疗?最近,发表于《美国医学会杂志》(JAMA)的一项研究显示,超过七成(73%)非复杂性急性阑尾炎患者可用抗生素治愈。JAMA的这项临床试验从2009年11月开始,到2012年6月份结束,共纳入530名18-60岁经CT确诊为非复杂性急性阑尾炎患者。病人被随机分配到早期急性阑尾炎切除组和抗生素治疗组,随访1年。抗生素治疗组病人接受静脉注射

NEJM:克罗恩病或导致口面部炎症!

一名28岁的青年男子在6年前被诊断患有克罗恩病,尽管在随后的治疗过程中有使用免疫抑制剂和生物疗法进行治疗,但在2年前还是出现了口面部肉芽肿炎症的现象(图A与B所示)。而此前他曾因肠瘘疾病行过外科回肠造口术。通过磁共振成像与造影剂显影显示口面部的病灶是由于口腔黏膜发炎导致出现了orocutaneous瘘管(如图C所示)。在牙齿和窦道内刮取组织检测显示为肉芽肿性炎症,但未见有感染性的物质。经明确诊断,

Hum Reprod Update:对需要接受人工授精(IVF)的女性保守治疗子宫内膜异位卵巢囊肿的风险评估

摘要背景:传统手术治疗卵巢子宫内膜异位的卵巢囊肿所使用的腹腔镜剥离技术最近因手术相关的卵巢储备伤害被质疑。根据现有指南建议,子宫内膜异位,平均直径小于4厘米,无需在IVF过程前系统摘除。然而,保守治疗可能有一些潜在的弊端和风险。子宫内膜异位的的存在理论上可能与过度刺激卵巢的应激、卵母细胞的能力相关,卵母细胞的检索可能是更加困难和危险的。该疾病的过程中可能会进展,此后妊娠结局可能会受到影响,并在以后